公开(公告)号：US20210333281A1

公开(公告)日：2021-10-28

申请号：US17282218

申请日：2019-10-02

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro Funahashi ,  Yukinori Minoshima ,  Michio Kanekiyo ,  Saori Miyano ,  Taisuke Hoshi

IPC: G01N33/574 ,  A61K31/47 ,  A61P35/00 ,  C12Q1/6886

Abstract: Biomarkers are provided that predict whether a subject having a hepatocellular carcinoma is responsive to a therapy comprising soratenib or a pharmaceutically acceptable salt thereof. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a hepatocellular carcinoma.